Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Lyell Immunopharma reported Q1 net loss of $24.2 million, a significant improvement from the prior year, driven by lower R&D and G&A expenses and a gain on its securities purchase agreement. The company closed the second $50 million tranche of its private placement at $25.61 per share, ending the quarter with $261 million in cash to fund operations into Q3 2027.
Key figures
- Revenue
- 2000
- Offering Price
- 25.61
- Runway
- Q3 2027
- Net loss
- 24200000
- Ga expenses
- 9600000
- Rd expenses
- 36600000
- Cash position
- 261000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.